CSIRO partners with Cicada to translate ‘superbug’ research
17 November 2021
The national science agency has partnered with a deep tech incubator to try and build out a local industry for antimicrobial resistance products, warning the pipeline for new “superbug” treatments is running dry.
CSIRO and Sydney deep tech incubator Cicada Innovations will offer local SMEs and researchers free training to commercialise their work into solutions for antimicrobial resistance (AMR), the emerging global public health threat where disease causing germs stop responding to medicine.
Further reading: CSIRO
Author(s): Joseph Brookes
Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
